51,752 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Trust Point Inc.

Trust Point Inc. purchased a new position in Pfizer Inc. (NYSE:PFEFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 51,752 shares of the biopharmaceutical company’s stock, valued at approximately $1,490,000.

Several other hedge funds have also recently added to or reduced their stakes in PFE. Moneta Group Investment Advisors LLC raised its position in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Norges Bank bought a new stake in Pfizer during the fourth quarter worth about $3,150,472,000. Charles Schwab Investment Management Inc. grew its stake in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley grew its stake in Pfizer by 10.3% during the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Pfizer during the first quarter worth about $311,238,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Barclays decreased their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday. Finally, Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $36.88.

View Our Latest Research Report on PFE

Pfizer Stock Down 0.4 %

Shares of NYSE:PFE traded down $0.11 during midday trading on Wednesday, reaching $27.44. 14,854,476 shares of the company were exchanged, compared to its average volume of 42,932,930. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $42.22. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a fifty day simple moving average of $27.41 and a two-hundred day simple moving average of $29.25. The firm has a market cap of $155.38 billion, a PE ratio of 76.11, a P/E/G ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the business posted $1.14 earnings per share. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.